ANCN
Anchiano Therapeutics
–
Index: NASDAQ; Sector: ; Industry: ;
Marketcap: –; Volume: 75.49K; AvgVol 3m: 97.27K; Beta: –;
Cost estimate:
P/E: –; EPS: –; EPS growth quarter/prev quarter: ;
EPS growth this year: 91.10%; EPS growth past 5 years: ;
EPS ttm: -2.67;
P/S: ; P/B: 01.07; P/Cashflow: ; P/FCF: ;
Sales: –; Sales growth quarter/prev quarter: ; Sales growth past 5 years: ;
Profitability:
Gross Margin: ; Profit Margin: ; Operating Margin: ;
ROA – return on assets: ; ROE – return on equity: ; LT Debt/Equity: ; Total Debt/Equity: ;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 18.97%; Insider Transactions:0.00%;
Institutional Ownership: 27.81%; Institutional Transactions: ;
Data update: 07/10/2020.